Retatrutide Phase 2 trial (NCT04867785)
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 281
- actual
- Start
- 13 May 2021 (actual)
- Primary completion
- 8 Jul 2022 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 0.5 milligrams (mg) LY3437943 | Experimental | Drug: LY3437943 | Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW). |
| 4 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW. |
| 4 mg LY3437943 (4 mg) | Experimental | Drug: LY3437943 | Participants received 4 mg LY3437943 administered as SC injection QW. |
| 8 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW. |
| 8 mg LY3437943 (4 mg) | Experimental | Drug: LY3437943 | Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW. |
| 12 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW. |
| 1.5 mg Dulaglutide | Active comparator | Drug: Dulaglutide | Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW. |
| Placebo | Placebo comparator | Drug: Placebo | Participants received placebo administered as SC injection QW. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | Baseline, 24 Weeks |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in HbA1c | Baseline, 24 Weeks |
| Change From Baseline in HbA1c | Baseline, 36 Weeks |
| Percentage of Participants Reaching HbA1c <7.0% | Week 24 |
| Percentage of Participant Reaching HbA1c <7.0% | Week 36 |
| Change From Baseline in Fasting Blood Glucose (FBG) | Baseline, 24 Weeks |
| Change From Baseline in Fasting Blood Glucose (FBG) | Baseline, 36 Weeks |
| Change From Baseline in Body Weight | Baseline, 24 Weeks |
| Change From Baseline in Body Weight | Baseline, 36 Weeks |
| Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943 | Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04867785.
The type 2 diabetes phase 2 trial of retatrutide
Participants were randomised 2:2:2:1:1:1:1:2 to placebo, dulaglutide 1.5 mg or retatrutide maintenance doses from 0.5 mg to 12 mg weekly.[2]
At 36 weeks bodyweight fell by 3.19% on retatrutide 0.5 mg and by 16.94% on 12 mg, against 3.00% on placebo and 2.02% on dulaglutide.[2]
Mild-to-moderate gastrointestinal events were reported in 67 (35%) of 190 retatrutide participants and six (13%) of 45 on placebo.[2]
Body composition substudy
Total fat mass fell 4.9% on 0.5 mg, 15.2% on pooled 4 mg, 26.1% on pooled 8 mg and 23.2% on 12 mg, against 4.5% on placebo.[3]
The authors reported that lean mass loss, as a share of weight lost, was similar to other obesity treatments.[3]
Appetite and eating behaviour
Appetite scores and the Eating Inventory were analysed at 24 and 36 weeks in 275 adults with type 2 diabetes.[4]
Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint, correlated with weight loss at week 36 (r = 0.28, 0.36 and 0.31).[4]
Sources
- 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
- 3Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 4Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism · 2025PMID 40916752Accessed 2 Oct 2026
Found an error? Report a correction.